Table 1 Summary of immunohistochemical and histological outcomes.
From: Cuprizone feed formulation influences the extent of demyelinating disease pathology
Outcome measure | Cuprizone pellet relative to control pellet | Cuprizone powder relative to control powder | Cuprizone pellet relative to cuprizone powder | Control powder relative to control pellet | ||||
|---|---|---|---|---|---|---|---|---|
Rostral | Caudal | Rostral | Caudal | Rostral | Caudal | Rostral | Caudal | |
Astrocyte reactivity | ↑↑ | ↑ | ↑ | – | – | ↑ | – | – |
Microglial activation | ↑↑ | ↑↑ | ↑ | – | – | ↑↑ | – | – |
Protein nitration | – | ↑↑ | ↑↑ | – | ↓↓ | ↑ | – | – |
DNA damage | ↑ | ↑↑ | – | ↑ | – | – | – | – |
Area of corpus callosum | ↓ | ↑↑ | – | ↑ | – | – | – | – |
Hoechst+ cells | – | – | – | – | – | – | – | – |
Olig2+ cells | ↓↓ | – | – | – | – | ↑ | ↓↓ | ↓↓ |
PDGFRα+ cells | – | ↑↑ | – | ↑↑ | – | – | – | – |
Olig2+/PDGFRα+ cells | – | ↑ | – | ↑ | – | – | – | – |
ASPA+ cells | ↓↓ | ↓↓ | – | ↓↓ | – | – | ↓ | – |
CC1+ cells | – | ↓ | – | – | – | – | ↓ | – |
Myelination | – | ↓ | – | – | – | – | – | – |
